Peptide research profile

AOD9604

Also known as AOD-9604 · Tyr-hGH177-191

A synthetic C-terminal growth-hormone fragment developed for obesity research. Human trials found acceptable short-term tolerability, but the pivotal phase 2b program did not establish weight-loss efficacy.

  • Metabolic research
Human trials2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The 250 mcg daily calculator row is an unofficial recorded preset, not the regimen validated by the failed obesity program. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset250 mcg / day
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposureNot established for injection
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Drug amount and device markings are different quantities. The calculator converts mass into volume, syringe units, or pen clicks.

Schedule literacy

Patterns described in source material

  • Daily in the recorded preset

    The cadence represented by the recorded calculator presets.

  • Oral doses varied across phase 2 studies

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context
  • 0.25–1 mg · Daily oral arms24-week phase 2b studyNo significant weight-loss efficacy

Human studies tested multiple IV and oral designs; the largest obesity trial did not meet its efficacy endpoint.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Obesity drug development

    AOD9604 advanced through several randomized clinical studies.

  • 02

    Metabolic mechanism

    Preclinical work explored lipolysis without full-length GH signaling.

  • 03

    Human tolerability

    Six trials were summarized for glucose, IGF-1, immunogenicity, and adverse events.

  • 04

    Negative efficacy result

    The large 24-week phase 2b trial failed its primary weight-loss endpoint.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    Six-trial safety summary

    Published pooled safety reporting found no GH-like IGF-1 or glucose signal over the studied periods.

  • Human

    Phase 2b efficacy failure

    Development for obesity stopped after no significant weight-loss benefit in the larger 24-week study.

  • Animal

    Preclinical lipolysis signal

    Rodent findings motivated clinical development but did not translate into pivotal efficacy.

Recorded protocol library

Amounts recorded for AOD9604

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Dose · lower endpoint

    100 mcg

    Sign in for schedule, duration and source context.

  • 02

    Recorded reference

    250 mcg

    Sign in for schedule, duration and source context.

  • 03

    Dose · upper endpoint

    500 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Synthetic hGH C-terminal fragment
Sequence
YLRIVQCRSVEGSCGF
Amino acids
16
Approx. MW
1815.1 Da
Origin / design
Tyr-hGH177-191 analogue designed to separate lipolytic from GH/IGF-1 effects

Important limitations

  • A tolerability signal is not evidence of efficacy.
  • The pivotal negative trial is central to interpreting marketing claims.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Safety and Tolerability of the Hexadecapeptide AOD9604 in HumansJournal of Endocrinology and Metabolism · 2013 · Human
  2. Obesity pharmacotherapy: current perspectives and future directionsCurrent Cardiology Reviews · 2013 · Review

Related profiles